Elan shares jump 10 per cent on Alzheimer’s drug results

Elan’s new drug is being watched carefully as it has the potential to generate several billion euro in revenue, writes Samantha McCaughren, Business Correspondent.

21st June, 2008

Elan’s new drug is being watched carefully as it has the potential to generate several billion euro in revenue, writes Samantha McCaughren, Business Correspondent.

Elan revealed encouraging results for its Alzheimer’s drug last week and the release of further details next month is being described by some US commentators as ‘‘the biggest biotech event of the year’’.

The drug, known as AAB001or bapineuzumab, has the potential to...

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

The year in review

Legacy Richie Oakley 1 year ago

Newsround: What Thursday’s papers say

Legacy Leanna Byrne 5 years ago

More cycle routes, expansion of Luas to Bray and new bus network proposed

Legacy Digital Desk 5 years ago